. Author manuscript; available in PMC: 2018 Jul 2.

Published in final edited form as: Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):73–79. doi: 10.1097/MED.0000000000000311

Table 1.

List of current SGLT2 inhibitors.

Generic Name	Brand Name	Available Doses (mg)	Administration
canagliflozin^a	Invokana®	100, 300	qam before 1^st meal
dapagliflozin^a	Farxiga^™	5, 10	qam
empagliflozin^a	Jardiance®	10, 25	qam
canagliflozin/metformin^a	Invokamet®	50/500, 50/1000, 150/500, 150/1000	BID with meals, max dose 300mg/2000mg
dapagliflozin/metformin^a	Xigduo^™ XR	5/500, 5/1000, 10/500, 10/1000	qam with food, max dose 10mg/2000mg
empagliflozin/metformin^a	Synjardy®	5/500, 5/1000, 12.5/500, 12.5/1000	BID with meals, max dose 25mg/2000mg
empagliflozin/linagliptin^a	Glyxambi®	10/5, 25/5	qam
Ipragliflozin^b	Suglat®	25, 50	qam, max dose 100mg
tofogliflozin^b ^c	Apleway®, Deberza®	20	qam
luseogliflozin^c
remogliflozin etabonate^c
ertugliflozin^c
sotagliflozin^c

FDA and EMA approved,

Ministry of Health, Labour and Welfare approved in Japan,

currently in clinical trials or seeking market approval; qam taken once daily in the morning, BID twice daily